Performance of a one-step fecal sample-based test for diagnosis of Helicobacter pylori infection in primary care and mass screening settings  by Lee, Yi-Chia et al.
Journal of the Formosan Medical Association (2014) 113, 899e907Available online at www.sciencedirect.com
journal homepage: www.jfma-onl ine.comORIGINAL ARTICLE
Performance of a one-step fecal
sample-based test for diagnosis of
Helicobacter pylori infection in primary
care and mass screening settingsYi-Chia Lee a,b, Ping-Huei Tseng a, Jyh-Ming Liou a,
Mei-Jyh Chen a,c, Chien-Chuan Chen a, Chia-Hung Tu a,
Tsung-Hsien Chiang a,c, Han-Mo Chiu a, Chien-Fang Lai d,
Jhon-Chun Ho d, Ming-Shiang Wu a,e,*aDepartment of Internal Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
bDivision of Biostatistics, Graduate Institute of Epidemiology and Preventive Medicine,
College of Public Health, National Taiwan University, Taipei, Taiwan
cDepartment of Integrated Diagnostic & Therapeutics, National Taiwan University Hospital, Taipei, Taiwan
dResearch and Development, Firstep Bioresearch Incorporation, Tainan, Taiwan
eDepartment of Primary Care Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
Received 10 February 2012; received in revised form 21 April 2012; accepted 21 May 2012KEYWORDS
Helicobacter pylori;
mass screening;
stool antigen test* Corresponding author. Department
E-mail address: mingshiang@ntu.e
0929-6646/$ - see front matter Copyr
http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: An alternative screening test is needed to efficiently eradicate Helico-
bacter pylori from a population with prevalent upper gastrointestinal lesions. We evaluated
the performance of a new one-step fecal test for H. pylori for diagnosis of H. pylori infection
in Taiwan.
Methods: We developed a fecal test to detect H. pylori based on the immunochronomato-
graphic assay and a mixture of monoclonal antibodies. We first recruited symptomatic patients
from the primary care setting to evaluate fecal test performance using a reference standard
consisting of 13C urea breath test, rapid urease test, and histology. We also compared the
performance of the fecal test with that of others. Next, we recruited asymptomatic partici-
pants from the mass screening setting to evaluate population attendance for the fecal test
and compared its performance with that of 13C urea breath test.
Results: In the primary care setting, 117 patients were recruited; H. pylori infection was
confirmed in 58 (49.6%). Fecal test sensitivity, specificity, positive and negative predictiveof Internal Medicine, National Taiwan University Hospital, 7, Chung-Shan South Road, Taipei, Taiwan.
du.tw (M.-S. Wu).
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900 Y.-C. Lee et al.values, and accuracy were 88.0% [95% confidence interval (CI): 79.6e96.4%], 100%, 100%, 89.4%
(95% CI, 82.0e96.8%), and 94% (95% CI, 89.7e98.3%), respectively. Fecal test specificity and
positive predictive value were significantly higher than those of the serological test, whereas
the sensitivity and negative predictive value were lower than those of the 13C urea breath test
(p < 0.05). In the mass screening setting, 2720 of 3520 invited individuals participated (77.3%;
95% CI, 76e78.7%); 649 (23.9%) showed positive results. Concordance rate and kappa statistic
between the fecal test and 13C urea breath test were 91.7% (563/614; 95% CI, 89.9e94.1%) and
0.78 (95% CI, 0.73e0.84), respectively.
Conclusion: Given the acceptable sensitivity, excellent specificity, and high participation rate
to screening, the one-step H. pylori stool antigen test is feasible for wide application in the
community.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Chronic insidious infection by Helicobacter pylori can lead
to gastritis, peptic ulcer disease, and gastric cancer, and
research attention has increased in noninvasive methods
that are able to identify carriers at the presymptomatic
stage.1,2 Past efforts based on the serological test or the 13C
urea breath test have been limited by the fact that
participants are needed to attend the local screening
units,3 professionals are required to perform the test, and,
specifically for the former, serological test results may
remain positive many years after the elimination of
H. pylori. Therefore, an alternative screening test is
needed to efficiently eradicate H. pylori from a community
population with prevalent upper gastrointestinal lesions.4
The ideal screening test should be able to reach asymp-
tomatic patients who do not attend the screening unit,
allow sampling of biospecimens to be done at home, and
provide easy interpretation of results without the need of
technical expertise.
Lessons from colon cancer screening have demonstrated
that a fecal sample-based test can possibly meet the above
requirements5; however, the benefit of such a test for
cancer prevention depends on test performance.6 A fecal
sample-based test is also available for the diagnosis of H.
pylori infection through the detection of H. pylori antigens
in feces using specific antibodies. However, the perfor-
mance of H. pylori fecal tests varies across studies.7e9 This
heterogeneity is mainly related to the difference in
biochemical designs of the testsdthat is, an enzyme
immunoassay or an immunochromatographic assaydand to
the antibody selection, such as monoclonal or polyclonal
antibodies. The biochemical design of the immunochro-
matographic assay satisfies the needs of first-line health-
care workers in the public health centers and primary care
clinics who do not have laboratory facilities but must effi-
ciently identify H. pylori carriers in the community and
initiate treatment. As for antibody selection, the use of
monoclonal antibody technology is reported to produce
more specific results. However, in the Taiwanese pop-
ulation, which may be considered a typical presentation of
Asian populations, the prevalence rate of H. pylori infec-
tion is high and bacterial strains are heterogeneous, so
a false positive result is not uncommon (9e18%) when the
fecal test is based on a single monoclonal antibody; as such,a positive fecal test result has an error rate of 10e15% and
does not completely guarantee positive H. pylori
infection.10e12 Such a shortcoming may become a serious
concern when a mass screening program is being adminis-
tered in the community and may lead to unnecessary
workups and treatment subsequently.13 Therefore, it is
worthwhile to develop a new fecal test with specific anti-
bodies tailored to the local H. pylori strains.14
The purpose of this study was to develop and evaluate
the performance of a new one-step fecal test for diagnosis
of H. pylori infection in Taiwan. We had two priorities in
this study: the first was to develop the new one-step fecal
test based on the immunochromatographic assay using
a mixture of monoclonal antibodies and to evaluate its
performance in a primary care setting. Theoretically, the
specificity of such a test can be maintained based on the
monoclonal characteristics while the coverage of different
H. pylori strains would be increased by mixing multiple
monoclonal antibodies. The second priority was to evaluate
whether such a rapid and convenient test could attract
asymptomatic individuals to attend mass screening for H.
pylori infection, while reserving the 13C urea breath test or
other invasive tests as second-stage confirmatory tests.Materials and methods
Participants and study design
This prospective study was conducted to evaluate the
performance of the fecal H. pylori test in the primary care
setting as well as in the mass screening setting. In the first
part of the study, we recruited consecutive symptomatic
patients referred fromtheprimary care setting andvalidated
the performance of a new one-step H. pylori stool antigen
test using a reference standard consisting of two invasive
tests (rapid urease test and histology) and one noninvasive
test (13C urea breath test). In addition to the performance
comparison between the fecal test and the above three
tests, we further evaluated the value of the fecal test on the
diagnosis of active infection, rather than a previous one, by
comparing its performance with that of a serological test
known to be limited in differentiation.15
In the second part of study, we invited asymptomatic
individuals who underwent health screening to receive the
Figure 1 Representative test results of the one-step Heli-
cobacter pylori stool antigen test. The result was considered
positive when both the control and result lines appeared in the
window (upper cassette) and negative when only the control
line was observed (lower cassette).
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those based on the 13C urea breath test as both tests are
the recommended methods for use in the community.2
Special attention was paid to the participation rate in this
mass screening setting because it was similar to the wide
implementation of the fecal test in the community.
All participants provided informed consent to partici-
pate and the Ethics Committee of the National Taiwan
University Hospital approved both studies (nos. 200905076R
and 201101016RC, respectively).
One-step H. pylori stool antigen test
We developed a new one-step H. pylori fecal test using
a lateral flow chromatographic technique with a blend of
mouse anti-H. pylori monoclonal antibodies to qualitatively
detect H. pylori antigens in stool samples (Easy One Step
Test; Firstep Bioresearch, Inc., Tainan, Taiwan). This fecal
test consisted of a sampling tube and a test cassette. The
sampling tube contained buffer to stabilize stool antigens,
and the test cassette included a pad containing colloid gold
particles conjugated to the antibodies. Below the conju-
gate pad was a nitrocellulose membrane containing
a RESULT region and a CONTROL region. The RESULT region
was coated with paired antibodies to H. pylori antigens,
and the CONTROL region was coated with anti-rabbit
secondary antibodies.
Participants were asked to use the sampling tubes to
collect their fecal samples 1 day before the endoscopic
examination. On the examination day, the sampling tube
was returned, and two or three drops of the collected
sample were immediately dropped into the test cassette by
a technician. The results were interpreted 5 minutes later.
When H. pylori antigens were present in the stool sample,
the colloid gold complex conjugated with the antigens in the
conjugate pad to form an antigeneantibody complex. This
complexmoved to the RESULTregion by capillary action, and
a pink-red line would become visible when the anti-
geneantibody complex formed, indicating a positive result
for H. pylori infection. When the H. pylori-specific antigens
were absent in the stool sample, no color line would be
visible in the RESULT region, indicating a negative result. A
pink-red line would be always present in the CONTROL
region, regardless of whether or not the H. pylori antigens
were present, which served as a procedural indicator to
confirm that sufficient volume had been added, proper flow
had been obtained, and reagent control was adequate.
Representative test results are demonstrated in Fig. 1.
The test results were separately interpreted by two
technicians, who were blinded from each other’s results
and did not know the true H. pylori infection status. When
a consensus could not be reached in cases with trace-line
readings, the final interpretation was made by a senior
physician.
Validation study in the primary care setting
We recruited patients who had been referred from the
primary care setting for upper endoscopic examination due
to the presence of upper gastrointestinal symptoms at the
National Taiwan University Hospital. We excluded thosewho were under 18 years of age, those who had received
proton-pump inhibitor treatments within the current
month, those who had received previous antibiotic treat-
ment for H. pylori infection, those who were already
diagnosed with malignancy, and pregnant women. Patients
collected their fecal samples at home, and the H. pylori
fecal test was returned and interpreted at the outpatient
clinics. Before endoscopy, patients underwent the 13C urea
breath test (Helico-Bt King Mark; Taiwan I-SO Biotec Co.,
Ltd, Taipei city, Taiwan). During endoscopy, gastric antral
mucosae samples were taken for the rapid urease test
(Campylobacter-like organism test; HelicotecUT, Strong
Biotech Corporation, Taipei city, Taiwan) and histologic
examination (routine hematoxylin and eosin stain and
additional Diff-Quik stain for uncertain cases), respectively.
As there was no single test that could be considered the
gold standard for the diagnosis of H. pylori infection, we
defined the reference standard for a positive H. pylori
infection as positive results for at least two of the above
three tests (i.e., 13C urea breath test, rapid urease test,
and histology).12 After endoscopy, participants also under-
went the serological test to measure the concentration of
circulating anti-H. pylori immunoglobulin G antibodies with
the commercially recommended cutoff value (Siemens
Healthcare Diagnostics, Inc., Tarrytown, NY, USA).Validation study in the mass screening setting
We enrolled consecutive individuals aged 18 years or older
who voluntarily underwent endoscopic screening as part of
a self-paid medical checkup at the same institute. This
screening program also included the fecal occult blood test
as a routine study. We excluded those who had overt
gastrointestinal symptoms such as dysphagia or abdominal
pain that normally would require a medical evaluation, and
those who had overt gastrointestinal bleeding such as
hematemesis, tarry stool, melena, and hematochezia.6
Before screening, each screenee was mailed a pamphlet
902 Y.-C. Lee et al.inviting him/her to participate in the study, and sampling
tubes were provided for both the fecal occult blood test
and the H. pylori stool antigen test. The fecal samples were
returned on the screening day and tested immediately.
Results of the H. pylori stool antigen test were compared
with those of the 13C urea breath test. In this mass
screening setting, the 13C urea breath test was an optional
study frequently performed when upper endoscopy showed
lesions suspiciously related to chronic H. pylori infection,
including gastritis, peptic ulcers, and gastric neoplasms,
and therefore it could be regarded as a confirmatory test
for H. pylori infection.
Statistical analysis
For descriptive findings, we presented quantitative data as
means  standard deviations (SDs), and categorical vari-
ables as percentages. In the first part of study, we deter-
mined the performance of the fecal test by comparing the
results of the fecal test with the aforementioned reference
standard to construct a 2  2 table and calculated the
sensitivity, specificity, positive and negative predictive
values, accuracy, and corresponding 95% confidence inter-
vals (CIs). The performance difference between the fecal
test and the other test was evaluated using the c2 test or
Fisher’s exact test when appropriate. We also performed
stratified analyses according to the patients’ clinical char-
acteristics to test whether the performance of the fecal
test would vary in certain subgroups of patients.
Second, in the mass screening setting, we paid special
attention to the attendance rate for receiving the H. pylori
fecal test. We also calculated the concordance rate and
kappa statistics between the results of the fecal test and
those of the 13C urea breath test. Statistical analyses were
performed with the statistical software package SAS version
9.2 (SAS Institute Inc., Cary, NC, USA).
Results
Validation study in the primary care setting
Performance of the fecal test
After excluding seven cases with incomplete workups, we
recruited a total of 117 symptomatic patients (46 men andTable 1 Performance of the one-step stool antigen test and
infection.
Test Performance m
Sensitivity (%) Specificity (%)
Stool antigen test 88.0 (79.6e96.4)a 100b
13C urea breath test 98.3 (95.0e100)a 96.6 (92.0e100)
Rapid urease test 91.4 (84.2e98.6) 100
Histology 91.4 (84.2e98.6) 94.9 (89.3e100)
Serology 96.6 (91.9e100) 91.5 (84.4e98.6)b
NPV Z negative predictive value; PPV Z positive predictive value.
a p < 0.05 for the comparison between the stool antigen test and t
b p < 0.05 for the comparison between the stool antigen test and t71 women) from July 2010 to December 2010 to the first
part of study. Their mean age was 48.1  14.8 years (range:
20e82 years), and 58 (49.6%), 53 (45.3%), and 56 (47.9%)
participants showed positive results for the 13C urea breath
test, rapid urease test, and histology, respectively. Based
on the reference standard, positive H. pylori infection was
diagnosed in 58 (49.6%). Trace-line readings that required
a third interpretation occurred in two cases (2/117, 1.71%;
95% CI, 0e4.06%). The sensitivity, specificity, positive and
negative predictive values, and accuracy of the fecal test
were 88.0%, 100%, 100%, 89.4%, and 94.0%, respectively.
Comparing performance between the fecal test and other
tests
As shown in Table 1, the performance of the fecal test was
close to that of the rapid urease test; both showed excel-
lent specificity and positive predictive value. The compar-
ison between the performance of the fecal test and that of
the 13C urea breath test showed that the sensitivity and
negative predictive value of the 13C urea breath test were
significantly higher than those of the fecal test (p < 0.05).
The comparison between the performance of the fecal test
and that of the serological test showed that the specificity
and positive predictive value of the fecal test were signif-
icantly better than those of the serological test (p < 0.05).
Stratified analyses
Stratified analyses according to the clinical character-
isticsdincluding age, sex, body mass index, alcohol user,
endoscopic esophagitis, peptic ulcer disease, gastric
atrophy, or intestinal metaplasiaddid not significantly
affect the performance of the fecal test (Table 2).
However, there was a modest decrease in the test sensi-
tivity in smokers (smoker vs. nonsmoker: 70% vs. 92%),
barely reaching statistical significance (p Z 0.07).
Validation study in the mass screening setting
Performance of the fecal test
Between March 2011 and August 2011, a total of 3520
asymptomatic individuals were invited, and 2720 of them
participated in the second part of the study, yielding
a participation rate of 77.3% (95% CI, 76e78.7%). The
demographic characteristics of these participants (male
sex: 59.1%; mean age: 52.7  11.5 years; range 19e92other tests in the diagnosis of current Helicobacter pylori
easure (95% confidence interval)
PPV (%) NPV (%) Accuracy (%)
100b 89.4 (82.0e96.8)a 94.0 (89.7e98.3)
96.6 (92.0e100) 98.3 (95.0e100)a 97.4 (94.5e100)
100 92.2 (85.6e98.8) 95.7 (92.0e99.4)
94.6 (88.7e100) 91.8 (84.9e98.7) 93.2 (88.6e97.8)
91.8 (84.9e98.7)b 96.4 (91.5e100) 94.0 (89.7e98.3)
he 13C urea breath test in sensitivity and NPV.
he serological test in specificity and PPV.
Table 2 Performance of the one-step Helicobacter pylori stool antigen test, stratified by the demographic, endoscopic, and
histological characteristics.
Characteristics Number Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%)
Age
50 y 59 89.2 100 100 84.6 94.8
<50 y 58 85.7 100 100 92.5 94.8
Sex
Male 46 85 100 100 89.7 93.5
Female 71 89.5 100 100 89.2 94.4
Body mass index
24 kg/m2 42 88.5 100 100 84.2 92.9
<24 kg/m2 75 87.5 100 100 91.5 94.7
Smokingonce per week
Yes 24 70 100 100 82.3 87.5
No 93 91.7 100 100 91.8 95.7
Alcoholonce per week
Yes 27 88.2 100 100 83.3 92.6
No 90 87.8 100 100 90.7 94.4
Reflux esophagitis
Yes 68 84.8 100 100 87.5 92.6
No 49 92 100 100 92.3 95.9
Peptic ulcer disease
Yes 40 89.7 100 100 78.6 92.5
No 77 86.2 100 100 92.3 94.8
Gastric atrophy or intestinal metaplasia
Yes 28 91.3 100 100 71.4 92.9
No 89 85.7 100 100 91.5 94.4
NPV Z negative predictive value; PPV Z positive predictive value.
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pants (male sex: 56.8%; mean age: 52.2  12.0 years;
range: 15e92 years). Among the participants, 649 (23.9%)
showed positive fecal test results, trace-line reading that
required the third interpretation occurred in 20 cases (20/
2720, 0.74%; 95% CI, 0.42e1.06%), and 614 (22.6%) also
received the 13C urea breath test.
Comparing performance between the fecal test and the
13C urea breath test
Regarding the concordant results between two tests, there
were 133 (21.7%) individuals with both positive results and
430 (70.0%) with both negative results. The concordance
rate between the results of the 13C urea breath test and the
fecal test was 91.7% (563/614; 95% CI, 89.9e94.1%), and
the kappa statistic was 0.78 (95% CI, 0.73e0.84), indicating
a substantial level in agreement.
Regarding the discordant results, there were 32 (5.2%)
individuals with positive 13C urea breath test but negative
fecal test results and 19 (3.1%) with negative 13C urea
breath test but positive fecal test results. Knowing that the
sensitivity of the 13C urea breath test was close to perfect
based on the first part of study, the false negative rate of
the fecal test in the mass screening setting was calculated
as 19.4% (32/165), which was close to the result of 12% (7/
58) estimated in the primary care setting (p Z 0.20).
Knowing that the specificity of the fecal test was perfectbased on the first part of study, the false positive rate of
the 13C urea breath test in the mass screening setting was
calculated as 6.9% (32/462), which was again similar to the
result of 3.4% (2/59) estimated in the primary care setting
(p Z 0.30).Discussion
In the present study, we showed that a rapid, near-patient
fecal test can achieve acceptable sensitivity and excellent
specificity in detecting H. pylori infection. We also found
that this type of fecal test can attract asymptomatic indi-
viduals to undergo mass screening. Both findings provide
a solid basis for the wide implementation of the fecal test
to screen H. pylori infection in the community.
Previous studies conducted in the Taiwanese population
(Table 310e12,16e22) have evaluated the accuracies of the H.
pylori stool antigen tests with the enzyme immunoassay
(86.9e97.5%), with the immunochromatographic assay
(90e91.5%), in pediatric patients (96.2%), in patients with
hemodialysis (97.5%), in patients with partial gastrectomy
(95.4%), and in patients with bleeding peptic ulcer (75%).
The performance of our rapid test is within the reported
range in adult patients (86.9e97.5%). In addition to
demonstrating satisfactory accuracy (94%), our immuno-
chromatographic assay has been iteratively calibrated in
Table 3 Representative studies evaluating stool antigen tests for the diagnosis of Helicobacter pylori infection in the Taiwan.
Authors; year Method; antibody Patients Performance measure
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
Accuracy
(%)
Chang et al16; 1999 Enzyme immunoassay;
polyclonal antibodya
33 adults 95 100 100 87.5 96.3
Ni et al17; 2000 Enzyme immunoassay;
polyclonal antibodyb
53 children 92.6 100 100 92.9 96.2
Wang et al18; 2001 Enzyme immunoassay;
polyclonal antibodya
80 ESRD patients 97.5 97.5 97.5 97.5 97.5
80 controls 97.9 96.9 97.9 96.9 97.5
Yu et al19; 2001 Enzyme immunoassay;
polyclonal antibodya
32 adults 88.9 92.9 94.1 86.7 90.6
Chang et al20; 2002 Enzyme immunoassay;
polyclonal antibodya
54 adults 94.3 89.5 94.3 89.5 92.6
Sheu et al21; 2002 Enzyme immunoassay;
polyclonal antibodya
108 patients with
partial gastrectomy
93 100 100 88.1 95.4
Wu et al10; 2003 Immunochromatographic
assay; monoclonal antibodyc
253 adults 95.8 91.1 90.4 96.1 NA
Lin et al22; 2006 Enzyme immunoassay;
polyclonal antibodyd
59 patients with
nonbleeding ulcers
93 93 93 93 93
92 patients with
bleeding ulcers
81 68 74 77 75
Lu et al11; 2006 Immunochromatographic assay;
monoclonal antibodyc
120 adults 96.8 82.8 85.7 96 90
Wu et al12; 2006 Enzyme immunoassay;
polyclonal antibodya
176 adults 83.8 90.9 92.2 81.4 86.9
Immunochromatographic assay;
monoclonal antibodyc
95.0 87.0 90.4 93.1 91.5
This study; 2012 Immunochromatographic assay;
Mixture of monoclonal
antibodies e
117 adults 88.0 100 100 89.4 94
2720 adults f 80.6 95.8 NA NA NA
a Premier Platinum HpSA (Meridian Diagnostics Inc., Cincinnati, OH, USA).
b HpSA Microwell EIA (Meridian Diagnostics Inc., Cincinnati, OH, USA).
c ImmunoCard STAT! HpSA (Meridian Bioscience, Inc., Cincinnati, OH, USA).
d Diagnostec H. pylori antigen EIA Kit (Diagnostec International Ltd, Hong Kong).
e Firstep Helicobacter pylori Antigen Rapid Test (Firstep Bioresearch Inc., Tainan city, Taiwan).
f Sensitivity and specificity of the fecal test in 2720 adults were estimated using the 13C urea breath test as the reference standard.
904 Y.-C. Lee et al.order to achieve a specificity that is much higher than
before (100% vs. 82.8e91.1%). The associated clinical
benefit is that the possibility for a false positive result is
minimized and the interpretation of results becomes very
straightforward. We also believe such a benefit may
outweigh the modest decrease in sensitivity because
second-line rescue tests are readily available.
Regarding other populations with prevalent H. pylori
infection in Asia, accuracy of fecal tests (Table 4)23e33 has
been reported with the enzyme immunoassay (86e98.3%),
with the immunochromatographic assay (88e94%), in adult
patients (86e97.1%), and in pediatric patients (94e96.5%);
these results were comparable to the reported perfor-
mance in the Taiwanese population. Among these other
fecal tests, the most similar fecal test to our antibody
design is an enzyme immunoassay using a multiple-
monoclonal-antibody design (Premier Platinum HpSA
PLUS; Meridian Bioscience Inc., Cincinnati, OH, USA). The
superiority of this test compared to other single-antibody-
based tests has been confirmed by studies conducted in
Vietnam, Turkey, and Japan with sensitivity and specificity
of 90e96% and 91e94.9%, respectively.30,32,34 This findingindicates that adjustment of the antibody formula accord-
ing to the local H. pylori strains is required, which may also
explain the heterogeneity in the reported performance
when the same H. pylori stool antigen test is applied in
different populations.
Factors suppressing the performance of the H. pylori
stool antigen test may include the use of proton pump
inhibitors or antibiotics, the presence of upper gastroin-
testinal bleeding, and the presence of liver cirrhosis.8 We
found a modest decrease of sensitivity in smokers. Although
the reason for the difference in this particular subset of
patients remains unclear, abstinence from smoking,
a common recommendation before 13C urea breath test and
during anti-H. pylori treatment, may be also recommended
before the fecal H. pylori test.
Our study may have limitations. First, we did not eval-
uate the performance of our fecal test in the post-
treatment period. The main reason for this omission is
that this type of post-treatment evaluation has been
reimbursed by the National Health Insurance with a 13C
urea breath test. In addition, our main purpose is to confirm
the applicability of the fecal test as the first-line screening
Table 4 Representative studies evaluating stool antigen tests for the diagnosis of Helicobacter pylori infection in other Asian populations.
Authors; year; area Method; antibody Patients Performance measure
Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%)
Wong et al23; 1999;
Hong Kong
Enzyme immunoassay; polyclonal antibodya 86 adults 86.0 100 100 87.5 92.9
Enzyme immunoassay; polyclonal antibodyb 90.7 100 100 91.1 95.2
Ito et al24; 2000;
Japan
Enzyme immunoassay; polyclonal antibodya 105 adults post treatment NA NA NA NA 97.1
Demiray et al25; 2001;
Turkey
Enzyme immunoassay; monoclonal antibodyc 22 patients with
bleeding ulcers
60 86 90 50 NA
Immunochromatographic assay;
monoclonal antibodyd
33 86 83 38 NA
Kato et al26; 2003;
Japan
Enzyme immunoassay; polyclonal antibodya 264 children 96.0 96.8 92.2 98.4 96.5
Kato et al27; 2004;
Japan
Enzyme immunoassay; polyclonal antibodya 182 children and adolescents 96.8 99.2 98.4 98.3 98.3
Immunochromatographic assay;
monoclonal antibodye
90.6 95.8 92.1 95.0 94.0
Kaklikkaya et al28; 2006;
Turkey
Immunochromatographic assay;
monoclonal antibodye
65 adults before treatment 70.6 70.6 100 100 NA
65 adults after treatment 84.2 64.7 72.7 78.6 NA
Yang and Seo29; 2008;
Republic of Korea
Enzyme immunoassay; polyclonal antibodya 131 pretreatment
tests in children
96.4 97.1 90 99 NA
Immunochromatographic assay;
monoclonal antibodye
96.4 100 100 99 NA
Enzyme immunoassay; polyclonal antibodya 33 post-treatment
tests in children
88.9 91.7 80 95.7 NA
Immunochromatographic assay;
monoclonal antibodye
88.9 91.7 80 95.7 NA
Nguyen et al30; 2008;
Vietnam
Enzyme immunoassay; monoclonal antibodiesf 232 children 96.6 94.9 NA NA NA
Deguchi et al31; 2009;
Japan
Enzyme immunoassay; polyclonal antibodya 150 post-treatment adults 87.0 97.5 NA NA NA
Enzyme immunoassay; monoclonal antibodyg 91.6 98.4 NA NA NA
Kesli et al32; 2010;
Turkey
Enzyme immunoassay; monoclonal antibodiesf 168 adults 90 91 85 94 90
Enzyme immunoassay; monoclonal antibodyh 77 91 83 87 86
Immunochromatographic assay;
monoclonal antibodyi
81 92 86 89 88
Choi et al33; 2011;
Republic of Korea
Enzyme immunoassay; polyclonal antibodyj 515 adults 93.1 94.6 95.1 92.3 93.8
ESRD Z end-stage renal disease; NA Z not available; NPV Z negative predictive value; PPV Z positive predictive value.
a Premier Platinum HpSA (Meridian Diagnostics Inc., Cincinnati, OH, USA).
b Apollo H. pylori Antigen Test (PUMC Pharmaceutical Co. Ltd, Beijing, China).
c Rapid STR_IP!HpSA (Meridian Bioscience, Inc., Cincinnati, OH, USA).
d Simple H. pylori antigen cassette test (Linear Chemicals, S.L., Montgat, Spain).
e ImmunoCard STAT! HpSA (Meridian Bioscience, Inc., Cincinnati, OH, USA).
f Premier Platinum HpSA PLUS (Meridian Bioscience, Inc., Cincinnati, OH, USA).
g Testmate H. pylori antigen (Wakamoto Pharmaceutical, Tokyo, Japan); Hp Ag test.
h Dia.Pro Diagnostic Bioprobes Srl (Milan, Italy).
i H. pylori fecal antigen test (Vegal Farmaceutica, Madrid, Spain).
j EZSTEP H. pylori (Dinona, Seoul, Republic of Korea).
O
n
e
-ste
p
H
e
lico
b
a
cte
r
p
ylo
ri
fe
ca
l
te
st
in
T
a
iw
a
n
905
906 Y.-C. Lee et al.tool, so we believe we have successfully reached our study
goal. Second, in the mass screening setting, we did not
exclude those who had recent use of proton-pump inhibi-
tors or antibiotics. These medications may reduce the
density and/or urease activity of H. pylori, and the sensi-
tivity for both the fecal test and the 13C urea breath test
may be underestimated.35 Third, despite the plausibility of
mass screening, the H. pylori stool antigen test has rarely
been applied in the asymptomatic population.33,36 Although
we have systematically clarified the effectiveness of the H.
pylori fecal test in both the primary care setting and the
mass screening setting, these individuals might still be
different from a community population that has a full
spectrum of demographics and socioeconomics. Nonethe-
less, our finding implies that a simultaneous two-in-one
Combo test (i.e., the H. pylori stool antigen test plus the
fecal occult blood test) is achievable since the population
attendance is high. This finding also indicates that knowl-
edge about the benefits of test-and-treat for H. pylori
infection may have been disseminated in an Asian pop-
ulation with prevalent upper gastrointestinal tract
disease.37 By contrast, although prevalence of colorectal
neoplasms is also increasing,38 knowledge about the bene-
fits of the fecal occult blood test remains insufficient and
has led to a low participation rate.39,40 We believe that an
additional fecal H. pylori test may be one solution to
overcome this issue. Therefore, this topic warrants further
investigation. Fourth, our results show that the 13C urea
breath test is more sensitive than the fecal antigen test so
it should be a better diagnostic tool for use in the primary
care setting, especially in the referred hospitals. However,
when targeting a large, mostly asymptomatic population in
the community, the cost-effectiveness becomes a relevant
concern. Compared with the fecal test, the 13C urea breath
test is more costly and the incremental cost to screen one
additional H. pylori carrier is estimated at US$230. This
issue should be carefully studied before implementing mass
screening in the community. Finally, the current study
validated the fecal test based on the Taiwanese population.
Its performance for other ethnic populations should be
validated in the future.
In conclusion, our one-step H. pylori stool antigen test
showed satisfactory sensitivity and excellent specificity in
diagnosing H. pylori infection. A high attendance for
receiving this test in the mass screening setting confirms
that this rapid and convenient test is feasible and advisable
for wide application in the community.Acknowledgments
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